J&J Increasingly Confident It Can Manage Stelara Cliff, but Work Remains

Why It Matters

Stelara accounts for a sizable share of J&J’s earnings, so its ability to sustain growth directly impacts the conglomerate’s financial outlook and signals how major pharma firms can navigate biosimilar disruption.

Key Takeaways

• Stelara Q4 2023 sales hit $13.5 billion, up 5% YoY
• First biosimilar launched in EU Q2 2024, capturing 15% market
• J&J targets 8% annual Stelara growth through 2028 via new indications
• Strategic price adjustments aim to offset biosimilar revenue erosion
• Analysts cut Stelara revenue forecasts by $1 billion, citing competition

Pulse Analysis

Stelara’s trajectory illustrates the broader challenge facing biologics as patents expire and biosimilars enter the market. After years of double‑digit growth, the drug’s U.S. and European sales have begun to feel the pressure of lower‑cost alternatives, especially after the European Medicines Agency approved the first Stelara biosimilar in early 2024. While the newcomer has secured roughly 15% of the EU market, J&J’s deep pipeline of new indications—particularly in ulcerative colitis and hidradenitis suppurativa—offers a pathway to retain prescribing physicians and patients who value the original formulation’s efficacy profile.

To counteract anticipated erosion, J&J is deploying a multi‑pronged strategy. The company is expanding Stelara’s label to include earlier‑line treatment options, negotiating value‑based contracts, and modestly adjusting pricing in key territories to stay competitive without sparking a price war. These moves are designed to sustain the drug’s contribution to the conglomerate’s earnings, which currently rely on Stelara for about 15% of total revenue. Analysts have responded by shaving roughly $1 billion from 2025 revenue projections, reflecting lingering doubts about the speed and scale of biosimilar uptake.

The outcome of J&J’s approach will resonate beyond its balance sheet. Success could set a precedent for how legacy biologics defend market share against cost‑driven competition, influencing pricing models and partnership structures across the industry. Conversely, a misstep may accelerate the shift toward biosimilars, prompting investors to reassess the risk profile of other high‑revenue biologics nearing patent cliffs. Stakeholders are watching closely as J&J aims for an 8% annual growth rate for Stelara through 2028, a target that hinges on both clinical expansion and agile commercial tactics.